JP2024102139A5 - - Google Patents

Info

Publication number

JP2024102139A5

JP2024102139A5 JP2024070307A JP2024070307A JP2024102139A5 JP 2024102139 A5 JP2024102139 A5 JP 2024102139A5 JP 2024070307 A JP2024070307 A JP 2024070307A JP 2024070307 A JP2024070307 A JP 2024070307A JP 2024102139 A5 JP2024102139 A5 JP 2024102139A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

cav3 antagonist

release component

plasma concentration

cav3

Prior art date

2024-04-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 28
• 101150110214 Cav3 gene Proteins 0.000 claims 16
• 239000005557 antagonist Substances 0.000 claims 16
• 230000036470 plasma concentration Effects 0.000 claims 8
• 239000012729 immediate-release (IR) formulation Substances 0.000 claims 6
• 238000013270 controlled release Methods 0.000 claims 5
• 150000003839 salts Chemical class 0.000 claims 5
• 208000016285 Movement disease Diseases 0.000 claims 4
• 239000002245 particle Substances 0.000 claims 4
• 208000018737 Parkinson disease Diseases 0.000 claims 3
• 206010044565 Tremor Diseases 0.000 claims 3
• 229920000642 polymer Polymers 0.000 claims 3
• 241000284466 Antarctothoa delta Species 0.000 claims 2
• 239000011324 bead Substances 0.000 claims 2
• 238000004090 dissolution Methods 0.000 claims 2
• 201000006517 essential tremor Diseases 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 239000006186 oral dosage form Substances 0.000 claims 2
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 239000011248 coating agent Substances 0.000 claims 1
• 238000000576 coating method Methods 0.000 claims 1
• 239000008103 glucose Substances 0.000 claims 1
• 229960001021 lactose monohydrate Drugs 0.000 claims 1
• 230000002618 waking effect Effects 0.000 claims 1